Koyfin Home > Directory > Health Care > Rigel Pharmaceuticals > Total Debt / Equity

Rigel Pharmaceuticals Total Debt / Equity Chart (RIGL)

Rigel Pharmaceuticals annual/quarterly Total Debt / Equity from 2010 to 2020. Debt to equity is a measure of leverage in a company and expressed as a ratio of the total debt relative to book value of equity.
  • Rigel Pharmaceuticals Total Debt / Equity for the quarter ending June 06, 2020 was $68m a 18.69% increase of 13m year over year
  • Rigel Pharmaceuticals Total Debt / Equity for the last 12 months ending June 06, 2020 was $68m a 18.69% increase of 13m year over year
  • Rigel Pharmaceuticals Annual Total Debt / Equity for 2019 was $67m a 99.29% increase of 67m from 2018
  • Rigel Pharmaceuticals Annual Total Debt / Equity for 2010 was $0m
Other Ratios Metrics:
  • Rigel Pharmaceuticals Total Debt / Capital for the quarter ending September 09, 2011 was $0m a -823.31% decrease of 0m year over year
  • Rigel Pharmaceuticals Other Liabilities for the quarter ending December 12, 2018 was $1m a 91.46% increase of 1m year over year
View Chart On Koyfin

Quarterly RIGL Total Debt / Equity Data

06/2020$68m
03/2020$44m
12/2019$67m
09/2019$55m
06/2019$38m
03/2019$33m
09/2011$0m
06/2011$0m
03/2011$0m
12/2010$0m

Annual RIGL Total Debt / Equity Data

2019$67m
2010$0m